Bladder Cancer Cells Maintain Paracrine IL-1 Signaling and IL-1Ra Sensitivity Following Chronic IL-1 Exposure
Cells · 30.07.2026 · 15 (15) · 1376
DOI: 10.3390/cells15151376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 30.07.2026. Verfasst von Jessica Gomez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX 75080, USA. Hauptthemen laut MEDLINE: Paracrine Communication, Signal Transduction, Interleukin-1, Interleukin 1 Receptor Antagonist Protein. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Cancer Society, The University of Texas at Dallas.
Abstract (Originalsprache)
Background
Cancer cells live in a dynamic and favorable ecosystem conducive to their growth and survival, known as the tumor microenvironment (TME). The TME is replete with various proinflammatory cell types that mediate crosstalk via the secretion of cytokines and chemokines to facilitate tumor growth and development. One cardinal proinflammatory cytokine that is present in the TME is interleukin-1 (IL-1). IL-1 promotes tumor angiogenesis and cancer cell metastasis; thus IL-1 receptor antagonist (IL-1Ra) is of clinical interest. Our lab previously reported that chronic exposure to exogenous IL-1 can select for cancer cells that evolve insensitivity to IL-1 signaling, thus rendering IL-1-targeting therapies, like IL-1Ra, irrelevant. While immune cells are the primary source of TME IL-1, cancer cells can also produce and secrete IL-1 to engage in autocrine and/or paracrine signaling. In this context, cancer cell exposure to multiple other sources of exogenous IL-1 beyond autocrine production might also amplify extrinsic IL-1 signaling in these cells, but the consequences of sustained amplified IL-1 signaling on the regulation, function, and therapeutic response of these cancer cells need to be explored.
Methods
Using the IL-1-secreting 5637 bladder cancer (BlCa) cell line, we generated chronic IL-1 sublines by spiking the growth medium with additional IL-1α or IL-1β chronically for 6 months. Once established, we assessed subline acute IL-1 sensitivity, paracrine signaling and response to IL-1Ra.
Results
Following chronic exposure to elevated exogenous IL-1 levels, the 5637 BlCa cell line retains sensitivity to acute IL-1 and IL-1Ra and maintains the ability to induce IL-1-dependent endothelial cell activation, which is reversed with IL-1Ra. These data suggest that for cancer cells that engage in cell autonomous IL-1 signaling, sustained extrinsic IL-1 exposure does not dampen IL-1 or IL-1Ra sensitivity, supporting the context-dependent use of IL-1 antagonists as rational therapeutics in both acute and chronic inflammatory TMEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX 75080, USA.
ORCID-Profile: Bernice David, Nikki A Delk
Förderung
- American Cancer Society
- The University of Texas at Dallas
Zitieren
APA
Gomez, J., Lakew, M., Wilkie, H., David, B., Taiwo, O., Dhar, R., Akula, A., Thasma, A., Cho, J., Sharma, N., Okafor, O., & Delk, N. A. (2026). Bladder Cancer Cells Maintain Paracrine IL-1 Signaling and IL-1Ra Sensitivity Following Chronic IL-1 Exposure. Cells, 15(15), 1376. https://doi.org/10.3390/cells15151376
Vancouver
Gomez J, Lakew M, Wilkie H, David B, Taiwo O, Dhar R, et al. Bladder Cancer Cells Maintain Paracrine IL-1 Signaling and IL-1Ra Sensitivity Following Chronic IL-1 Exposure. Cells. 2026;15(15):1376. doi:10.3390/cells15151376
BibTeX
@article{Gomez2026,
author = {Gomez, Jessica and Lakew, Meron and Wilkie, Haley and David, Bernice and Taiwo, Oluwatamilore and Dhar, Roopal and Akula, Anusha and Thasma, Akshaykumar and Cho, Jeffrey and Sharma, Neil and Okafor, Obinna and Delk, Nikki A},
title = {Bladder Cancer Cells Maintain Paracrine IL-1 Signaling and IL-1Ra Sensitivity Following Chronic IL-1 Exposure},
journal = {Cells},
year = {2026},
volume = {15},
number = {15},
pages = {1376},
doi = {10.3390/cells15151376}
}
EUVIMED